Bangalore, India -- (SBWIRE) -- 11/02/2016 -- Metabolic disorders occur as a result of disruption of chemical processes and conversions occurring in the cells and fluids of the body. This is mainly because of defects in the enzyme; all process in the body are controlled by enzymes. Any disruption in the pathways involved in the development and metabolism of carbohydrates, proteins, fats, and nucleic acids, results in the development of metabolic disorders.

Report forecast the global metabolic disorders therapeutics market to grow at a CAGR of 4.62% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global metabolic disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various metabolic disorders including diabetes, obesity, lysosomal storage diseases, and hypercholesterolemia.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Global Metabolic Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Novo Nordisk
- Sanofi
- Merck
- AstraZeneca
- Eli Lilly

Other prominent vendors
- AbbVie
- Actelion Pharmaceuticals
- Adocia
- Aegerion Pharmaceuticals
- Akros Pharma
- Alnylam Pharmaceuticals
- Amarin
- nAmgen
- Amicus Therapeutics
- Arbutus Biopharma
- Arena Pharmaceuticals
- Astellas Pharma
- Atheronova
- Aurobindo Pharma
- Baxalta
- Belrose Pharma
- BHV Pharma
- Biocon
- Biodel
- BioMarin
- Bionaturis
- Biosidus
- Biospherics
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Catabasis Pharmaceuticals
- Cerenis Therapeutics
- Chipscreen Biosciences
- Cipla
- CJ HealthCare
- CKD Bio
- Concord Biotech
- ConjuChem
- CureDm
- CymaBay Therapeutics
- Daewoong
- Daiichi Sankyo
- Dance Biopharm
- DiaMedica
- Diamyd Therapeutics
- Diasome Pharmaceuticals
- DiaVacs
- Dong-A ST
- Eisai
- Elcelyx Therapeutics
- Esperion Therapeutics
- Exsulin
- F. Hoffmann-La Roche
- Gan & Lee Pharmaceuticals
- Generex Biotechnology
- Genfit
- GlaxoSmithKline
- HanAll BioPharma
- Hanmi Pharmaceutical Company
- Hua Medicine
- Iltoo Pharma
- Intarcia Therapeutics
- InteKrin Therapeutics
- Intrexon
- Ionis Pharmaceuticals
- Islet Sciences
- ISU Abxis
- Janssen Pharmaceuticals
- Japan Tobacco
- JCR Pharmaceuticals
- JW Pharmaceuticals
- Kadmon Pharmaceuticals
- Kamada
- KinDex Pharmaceuticals
- Kissei
- Kotobuki
- Kowa Company
- Laboratoires SMB
- Lexicon Pharmaceuticals
- Ligand Pharmaceuticals
- Living Cell Technologies
- Livzon
- LIXTE Biotechnology
- Lupin
- MacroGenics
- Madrigal Pharmaceuticals
- MannKind
- MedImmune
- Melior Pharmaceuticals
- Merrion Pharmaceuticals
- Merz Pharmaceuticals
- Metabolic Solutions Development Company
- Mitsubishi Tanabe Pharma
- Mylan
- Neothetics
- Neuraltus Pharmaceuticals
- NGM Biopharmaceuticals
- NGM Biopharmaceuticals
- Norgine BV
- Novartis
- NuSirt Biopharma
- Oramed
- Orexigen Therapeutics
- Osiris Therapeutics
- Peptron
- Perle Biosciences
- Pfizer
- PhaseBio Pharmaceuticals
- Poxel
- Protalix Biotherapeutics
- Raptor
- Recordati
- Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals
- REGiMMUNE
- Rhythm Pharmaceuticals
- Saniona
- Santaris Pharma
- Santaris Pharma
- Serometrix
- Shionogi
- Shire
- Sigma-Tau
- Sirona Biochem
- Strongbridge Biopharma
- SUN Pharma
- Takeda
- Teva
- Thera technologies
- Theracos
- Toleranzia
- Tolerion
- Torrent Pharmaceuticals
- Transition Therapeutics
- UCB
- Utrecht Holdings
- VeroScience
- Vivus
- vTv Therapeutics
- XBiotech
- Xeris Pharmaceuticals
- XOMA
- Zafgen
- Zydus Cadila

Market driver
- Increase in academia-industry collaborations for drug development
- For a full, detailed list, view our report

Market challenge
- Low compliance and adherence rates
- For a full, detailed list, view our report

Market trend
- Increase in academia-industry collaborations for drug development
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 136 pages "Global Metabolic Disorders Therapeutics Market 2016-2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Pipeline portfolio, Market landscape, Market segmentation by type of disease, Global diabetes drugs market, Global hypercholesterolemia drugs market, Global lysosomal storage diseases market, Global anti-obesity drugs market, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/global-metabolic-disorders-therapeutics-market-2016-2020

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.